BAYN:XETRBayer AG Analysis

Bayer shares are trading at €36.16, comfortably above the computed support of €32.96 but still under the 20‑day SMA of €37.34 and the 50‑day SMA of €38.44, indicating a short‑term price weakness. The RSI sits at 43, suggesting neutral momentum, while the MACD histogram remains negative and the signal line is bearish, reinforcing a cautious technical outlook. Volatility is high at 35.7% over the past 30 days, yet the beta of roughly 0.25 points to limited market‑wide price swings. On the valuation side, the forward P/E of 7.68 is far below the industry average of 27.9, and the DCF‑derived fair value of €65.46 implies a potential upside of nearly 37% versus the current price. Dividend sustainability is questionable with a low yield of 0.3% and a payout ratio exceeding 160%.
The latest Q1 2026 results show a 4% sales increase to €13.4 bn, driven by growth in Crop Science and Consumer Health, which helps offset flat pharmaceutical performance and sizable litigation‑related cash outflows. Management reaffirmed the 2026 outlook, and the Crop Science division is on track with its five‑year plan, providing a catalyst for medium‑term earnings recovery. However, the company carries a high debt‑to‑equity ratio of 134% and a negative ROE, underscoring the need for disciplined cash‑flow management. Overall, the stock appears undervalued with significant upside potential, but investors should weigh the litigation and leverage risks against the emerging growth trends.